Zenith Drugs IPO: Allotment / Subscription Status, GMP, Price, Lot Size, Date and More

News: Zenith Drugs Limited, a pharmaceutical company specializing in manufacturing and trading high-quality, affordable medicines, is all set to launch its Initial Public Offering (IPO). If you’re curious about the details, read on to find out everything you need to know about the Zenith Drugs IPO.

Key Details

• IPO Date: The Zenith Drugs IPO opens for subscription on February 19, 2024, and closes on February 22, 2024.
• Price Band: The price band for Zenith Drugs IPO is set at ₹75 to ₹79 per share.
• Lot Size: The minimum lot size for an application is 1600 shares.
• Issue Size: The IPO comprises a fresh issue of 5,148,800 shares, aggregating up to ₹40.68 crores.
• Allotment Date: The allotment for the Zenith Drugs IPO is expected to be finalized on Friday, February 23, 2024.
• Listing Date: Zenith Drugs IPO will list on NSE SME with a tentative listing date fixed as Tuesday, February 27, 2024.

Investment Details

• Retail Investors: The minimum investment required by retail investors is ₹126,400 (for 1600 shares).
• High Net Worth Individuals (HNI): HNIs can invest in a minimum of 2 lots (3,200 shares), amounting to ₹252,800.

Incorporated in 2000, Zenith Drugs Limited adheres to WHO-GMP guidelines and has received ISO 9001:2015 certification from a respected EuroUK certification body. The company’s commitment to quality is evident in its range of generic drugs and affordable medicines.

Subscribe to Sarkari Result to stay informed. Get the latest celebrity news and detailed movie reviews in real-time. Keep up with the constantly changing world of entertainment with Sarkari Exam.

About Zenith Drugs Company :

Zenith Drugs Limited, incorporated in 2000, is a pharmaceutical company based in Indore, Madhya Pradesh, India. The company specializes in manufacturing and trading high-quality, affordable medicines, including generic drugs. Here are some key details about Zenith Drugs:

Quality Commitment: Zenith Drugs adheres to WHO-GMP guidelines and has received ISO 9001:2015 certification from a respected EuroUK certification body. This certification underscores the company’s dedication to maintaining high standards of quality.

Product Range: The company produces diverse formulations, including ORS powder, liquid orals, ointments, and capsules. These products reflect Zenith Drugs’ commitment to providing efficient, safe, and affordable healthcare solutions.

Financial Highlights:

1. Steady revenue growth from ₹7,340.17 lakhs in 2021 to ₹11,451.91 lakhs in 2023.
2. Equity nearly doubled from ₹895.27 lakhs in 2021 to ₹1,725.87 lakhs in 2023.
3. Profit after tax increased from ₹302.92 lakhs in 2021 to ₹515.33 lakhs in 2023.
4. Return on Net Worth (RoNW) remained high at 29.88% in 2023, indicating operational efficiency.
5. Diluted Earnings Per Share (EPS) significantly increased from ₹75.73 in 2021 to ₹128.82 in 2023.
6. Total assets more than doubled, reflecting significant investment in growth.
7. Net Asset Value (NAV) per equity share nearly doubled from ₹7.46 in 2021 to ₹14.37 in 2023.

The Zenith Drugs IPO presents an opportunity for investors to be part of a promising pharmaceutical venture. Keep an eye out for the listing date and consider your investment options wisely. Remember, investing always carries risks, so consult with financial experts before making any decisions.

Disclaimer: Please note that all content and tools on this website are provided for your convenience and are offered “as is” without warranties. The information provided, including any tool-generated output, is for informational purposes only and should not be considered investment advice or guarantees. Exercise caution, seek professional advice, and make independent judgments before acting on any information found on this site.